Citius Pharmaceuticals Inc CTXR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
-
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
-
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
-
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
-
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
-
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
-
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
Trading Information
- Previous Close Price
- $0.51
- Day Range
- $0.49–0.51
- 52-Week Range
- $0.48–2.19
- Bid/Ask
- $0.49 / $0.51
- Shares Outstanding
- 27.45M
- Market Cap
- $13.61M
- Volume/Avg
- 286,627 / 611,239
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.59
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 23
- Website
- https://www.citiuspharma.com
Valuation
|
Metric
|
CTXR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.18 |
Price/Sales | 1.59 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CTXR
|
|---|---|
Quick Ratio | 0.10 |
Current Ratio | 0.58 |
Interest Coverage | −119.66 |
Quick Ratio
CTXR
Profitability
|
Metric
|
CTXR
|
|---|---|
Return on Assets (Normalized) | −34.18% |
Return on Equity (Normalized) | −66.68% |
Return on Invested Capital (Normalized) | −58.68% |
Return on Assets
CTXR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|qvkJDYh | LOCK|cl^@% | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?&XVD>K | LOCK|Fn$R | $71B | |||
| argenx SE ADR
ARGX
| LOCK|wQ^K$@^ | LOCK|?^P | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|zz?@sf | LOCK|>@$ | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<l>!s$p | LOCK|@#Vq | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|g?^g>XC@ | LOCK|S^yq | $26B | |||
| Moderna Inc
MRNA
| LOCK|XK&Z!bj | LOCK|#mS | $25B | |||
| Incyte Corp
INCY
| LOCK|tD@YnWz | LOCK|nQn | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?V>v>&^ | LOCK|rCD | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|w&&qh$ | LOCK|tyP | $16B |
United States